Overview

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Status:
Recruiting
Trial end date:
2023-05-20
Target enrollment:
Participant gender:
Summary
In this single-arm study, patient with cervical cancer who had recurrence of the pelvic wall after surgery ± Abdominal aortic lymph node metastasis will be included to evaluate the efficacy and safety of camrelizumab combined with concurrent chemoradiation and subsequent maintenance therapy
Phase:
Phase 2
Details
Lead Sponsor:
Hunan Cancer Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Carboplatin